Literature DB >> 405590

Clinical immunity in acute gastroenteritis caused by Norwalk agent.

T A Parrino, D S Schreiber, J S Trier, A Z Kapikian, N R Blacklow.   

Abstract

To examine immunity in viral gastroenteritis, we challenged and then rechallenged 12 volunteers with Norwalk agent and evaluated symptoms, jejunal biopsies and serum antibody. With the first challenge, gastroenteritis developed in six volunteers but not in the others. When rechallenged 27 to 42 months later, the six who became ill initially again had gastroenteritis with jejunal lesions; in the six previously immune volunteers illness or jejunal lesions did not develop. Four of five ill volunteers had increases in serum antibody to Norwalk agent after both challenges. Serum antibody did not increase in three immune volunteers after either challenge. Four volunteers who had twice become ill underwent a third challenge four to eight weeks after their second illness. In one gastroenteritis developed; in three, it did not. These findings indicate two forms of immunity for viral gastroenteritis, one of short and the other of long duration. Factors other than serum antibody appear important in immunity to Norwalk gastroenteritis.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 405590     DOI: 10.1056/NEJM197707142970204

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  158 in total

1.  Norwalk virus-like particle hemagglutination by binding to h histo-blood group antigens.

Authors:  Anne M Hutson; Robert L Atmar; Donald M Marcus; Mary K Estes
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Genogroup II noroviruses efficiently bind to heparan sulfate proteoglycan associated with the cellular membrane.

Authors:  Masaru Tamura; Katsuro Natori; Masahiko Kobayashi; Tatsuo Miyamura; Naokazu Takeda
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

3.  Prevalence of antibody to the Norwalk virus in various countries.

Authors:  H B Greenberg; J Valdesuso; A Z Kapikian; R M Chanock; R G Wyatt; W Szmuness; J Larrick; J Kaplan; R H Gilman; D A Sack
Journal:  Infect Immun       Date:  1979-10       Impact factor: 3.441

4.  Diagnostic accuracy and analytical sensitivity of IDEIA Norovirus assay for routine screening of human norovirus.

Authors:  Verónica Costantini; LaDonna Grenz; Angela Fritzinger; David Lewis; Christianne Biggs; Antony Hale; Jan Vinjé
Journal:  J Clin Microbiol       Date:  2010-06-16       Impact factor: 5.948

5.  Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge.

Authors:  Anna D LoBue; Joseph M Thompson; Lisa Lindesmith; Robert E Johnston; Ralph S Baric
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

6.  A controlled human Schistosoma mansoni infection model to advance novel drugs, vaccines and diagnostics.

Authors:  Marie-Astrid Hoogerwerf; Jan Pieter R Koopman; Marijke C C Langenberg; Jacqueline J Janse; Janneke Kos-van Oosterhoud; Carola Feijt; Simon P Jochems; Claudia J de Dood; Roos van Schuijlenburg; Arifa Ozir-Fazalalikhan; Mikhael D Manurung; Erliyani Sartono; Martha T van der Beek; Béatrice M F Winkel; Petra H Verbeek-Menken; Koen A Stam; Fijs W B van Leeuwen; Pauline Meij; Angela van Diepen; Lisette van Lieshout; Govert J van Dam; Paul L A M Corstjens; Cornelis H Hokke; Maria Yazdanbakhsh; Leo G Visser; Meta Roestenberg
Journal:  Nat Med       Date:  2020-02-17       Impact factor: 53.440

Review 7.  Developments in understanding acquired immunity and innate susceptibility to norovirus and rotavirus gastroenteritis in children.

Authors:  Daniel C Payne; Umesh D Parashar; Benjamin A Lopman
Journal:  Curr Opin Pediatr       Date:  2015-02       Impact factor: 2.856

8.  Heterotypic humoral and cellular immune responses following Norwalk virus infection.

Authors:  Lisa C Lindesmith; Eric Donaldson; Juan Leon; Christine L Moe; Jeffrey A Frelinger; Robert E Johnston; David J Weber; Ralph S Baric
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

9.  Type I and type II interferons inhibit the translation of murine norovirus proteins.

Authors:  Harish Changotra; Yali Jia; Tara N Moore; Guangliang Liu; Shannon M Kahan; Stanislav V Sosnovtsev; Stephanie M Karst
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

10.  Herd immunity to GII.4 noroviruses is supported by outbreak patient sera.

Authors:  Jennifer L Cannon; Lisa C Lindesmith; Eric F Donaldson; Lauryn Saxe; Ralph S Baric; Jan Vinjé
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.